Compare · GILD vs RXRX
GILD vs RXRX
Side-by-side comparison of Gilead Sciences Inc. (GILD) and Recursion Pharmaceuticals Inc. (RXRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GILD and RXRX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $184.47B, about 96.8x RXRX ($1.91B).
- Over the past year, GILD is up 29.7% and RXRX is down 26.3% - GILD leads by 56.0 points.
- GILD has been more active in the news (12 items in the past 4 weeks vs 9 for RXRX).
- GILD has more recent analyst coverage (25 ratings vs 10 for RXRX).
- Company
- Gilead Sciences Inc.
- Recursion Pharmaceuticals Inc.
- Price
- $148.78+1.33%
- $3.56+9.71%
- Market cap
- $184.47B
- $1.91B
- 1M return
- +13.98%
- +18.27%
- 1Y return
- +29.69%
- -26.29%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1992
- 2021
- News (4w)
- 12
- 9
- Recent ratings
- 25
- 10
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Recursion Pharmaceuticals Inc.
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. It has four clinical-stage drug candidates focused on rare, monogenic diseases; and 33 additional programs in various stages of preclinical development. Recursion Pharmaceuticals, Inc. has strategic agreements with Bayer; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. The company was founded in 2013 and is based in Salt Lake City, Utah.
Latest GILD
- European Commission Expands Role of Gilead’s Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status
- Director Bluestone Jeffrey exercised 5,000 shares at a strike of $67.04 and sold $725,078 worth of shares (5,000 units at $145.02) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Financial Officer Dickinson Andrew D sold $415,080 worth of shares (3,000 units at $138.36) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 165,646 units (SEC Form 4)
- Chief Comm & Corp Aff Officer Mercier Johanna exercised 25,000 shares at a strike of $67.07 and sold $3,853,908 worth of shares (28,000 units at $137.64) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 118,234 units (SEC Form 4)
- EVP Gen Counsel, Legal & Comp Cain Wettan Keeley M covered exercise/tax liability with 2,908 shares and converted options into 6,002 shares, increasing direct ownership by 58% to 8,454 units (SEC Form 4)
- SEC Form S-3ASR filed by Gilead Sciences Inc.
- SEC Form 10-Q filed by Gilead Sciences Inc.
- CORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results
- Chairman & CEO O'Day Daniel Patrick sold $1,954,694 worth of shares (15,000 units at $130.31) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 592,133 units (SEC Form 4)
- Gilead Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Latest RXRX
- CEO and President Khan Najat covered exercise/tax liability with 80,498 shares, decreasing direct ownership by 4% to 2,095,298 units (SEC Form 4) (withholding tax)
- Chief Financial Officer Taylor Ben R covered exercise/tax liability with 25,018 shares, decreasing direct ownership by 2% to 1,076,858 units (SEC Form 4) (for withholding tax)
- Chief Scientific Officer Hallett David covered exercise/tax liability with 26,657 shares, decreasing direct ownership by 2% to 1,043,837 units (SEC Form 4) to cover taxes
- SEC Form SCHEDULE 13G filed by Recursion Pharmaceuticals Inc.
- Director Borgeson Blake sold $97,500 worth of shares (30,000 units at $3.25) as part of a pre-agreed trading plan, decreasing direct ownership by 0.48% to 6,188,287 units (SEC Form 4)
- SEC Form 10-Q filed by Recursion Pharmaceuticals Inc.
- Recursion Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program
- Recursion to Participate in Upcoming Investor Conferences
- Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules